This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Intimal hyperplasia	Phosphoinositide 3-kinase- γ (PI3K γ)	<p>Rodent studies suggest inhibiting PI3Kγ could help prevent intimal hyperplasia following vascular injury. In PI3Kγ^{-/-} mice, neointimal formation following vascular injury was lower than that in wild-type controls. In mice and rats, a selective small molecule PI3Kγ inhibitor decreased vascular injury-induced intimal hyperplasia compared with placebo. Next steps could include identifying drug-like, selective PI3Kγ inhibitors and evaluating the compounds in additional intimal hyperplasia models.</p> <p>Takeda Pharmaceutical Co. Ltd. and Infinity Pharmaceuticals Inc. have the oral PI3Kδ and PI3Kγ inhibitor IPI-145 in Phase III testing to treat chronic lymphocytic leukemia (CLL). The compound also is in Phase II or earlier testing to treat various hematologic malignancies, autoimmune conditions and inflammatory diseases.</p> <p>Infinity also has the PI3Kδ and PI3Kγ inhibitor IPI-443 in preclinical development for inflammatory diseases.</p> <p>Rhizen Pharmaceuticals S.A. has the PI3Kδ and PI3Kγ inhibitor RP6530 in Phase I testing to treat hematologic malignancies.</p> <p>SciBX 7(34); doi:10.1038/scibx.2014.1012 Published online Sept. 4, 2014</p>	Patent and licensing status unavailable	<p>Smirnova, N.F. <i>et al. J. Exp. Med.</i>; published online July 29, 2014; doi:10.1084/jem.20131276</p> <p>Contact: Muriel Laffargue, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France e-mail: muriel.laffargue@inserm.fr</p> <p>Contact: Stéphanie Gayral, same affiliation as above e-mail: stephanie.gayral@inserm.fr</p>